GO
Loading...

Sanofi SA

More

  • BERLIN, Jan 27- International donors pledged $7.5 billion on Tuesday to immunize 300 million children in poor countries against deadly diseases such as diarrhea and pneumonia. At a Global Alliance for Vaccines and Immunization conference in Berlin, Microsoft founder Bill Gates and the British government topped the donations list at $1.55 billion and $1.5...

  • LONDON, Jan 26- Pfizer is to cut the price of its pneumococcal vaccine Prevenar 13 by 6 percent to $3.10 per dose in poor countries as part of a commitment to the GAVI global vaccines alliance, the U.S. drugmaker said on Monday. Pfizer's move comes as GAVI holds a major funding conference in Berlin at which it hopes to raise $7.5 billion from donors to pay for increased...

  • DAVOS, Switzerland, Jan 21- Takeda Pharmaceutical, Japan's largest drugmaker, is ready to look at doing deals now that it has refocused operations, its incoming chief executive said on Wednesday. "We don't want to be passive and we don't want to watch the train passing," he told Reuters on the fringes of the World Economic Forum in Davos. As COO, Weber has overseen a...

  • DAVOS, Jan 21- Christophe Weber, chief operating officer of Takeda Pharmaceutical Co., said on Wednesday he had been approached in connection with the vacant chief executive post at French drugs group Sanofi but decided to stay put. I just arrived and I'm not the kind of guy who would jump like that, "the French national told Reuters on the sidelines of the World...

  • *AstraZeneca sees $3.5 bln sales, analysts' numbers lower. *AstraZeneca shares up 1.5 percent. LONDON, Jan 14- AstraZeneca's blood-thinning drug Brilinta cut the risk of death or heart attack in patients with a history of previous attacks, according to a major clinical trial that will boost hopes for the closely watched product.

  • *AstraZeneca shares up 1.5 percent. LONDON, Jan 14- AstraZeneca's blood-thinning drug Brilinta cut the risk of death or heart attack in patients with a history of previous attacks, according to a major clinical trial that will boost hopes for the product. But AstraZeneca Chief Executive Pascal Soriot has made it a top priority and the company flagged Brilinta's...

  • SAN FRANCISCO, Jan 12- Eli Lilly and Co said on Monday that U.S. insurers are increasing pressure on the price of diabetes medications as they switch coverage from certain drugs to others to trim costs. "We've definitely seen increased price competition, more by payers than the companies themselves," Lilly Chief Financial Officer Derica Rice said on Monday in an...

  • LONDON, Jan 12- European equities rebounded on Monday, led by airlines and auto stocks after positive updates by Continental and Lufthansa. Brent crude dropped below $49 a barrel on Monday, around its lowest since April 2009, hit by a global supply glut. "The tremendous oil price collapse is not adequately reflected in the airlines' share prices in my view," said...

  • *Peugeot buoyed by broker upgrade. LONDON, Jan 12- European equities gained on Monday, led by rising healthcare stocks, after Shire agreed to buy NPS Pharmaceuticals for $5.2 billion and Roche also struck a deal. Chemicals shares also performed well after U.S. investment bank Citigroup upgraded several European chemicals companies, including BASF.

  • Rise in healthcare stocks lifts European equities Monday, 12 Jan 2015 | 3:20 AM ET

    LONDON, Jan 12- A rise in healthcare shares, following renewed signs of industry consolidation after Shire Plc agreed to buy NPS Pharmaceuticals for $5.2 billion, lifted European equities on Monday. "The Shire deal is likely to mean that there will be no fresh bid speculation coming through on Shire itself, although the ongoing consolidation within the industry...

  • Jan 9- An experimental drug from Sanofi SA and Regeneron Pharmaceuticals was found to be effective in lowering "bad" cholesterol even when administered once every four weeks, instead of every two weeks. Sanofi SA and Regeneron are in a fierce race with Pfizer and Amgen Inc to bring their PCSK9 inhibitor to the market, which is expected to be worth billions if these...

  • Jan 6- KaloBios Pharmaceuticals Inc said it would discontinue the development of its drug for lung infections in cystic fibrosis patients after it failed in a mid-stage study, sending the company's shares down 62 percent in extended trading. The company said its drug, KB001-A, did not extend the time before cystic fibrosis patients had to take antibiotics for...

  • KaloBios drops lung infection drug, shares plunge Tuesday, 6 Jan 2015 | 4:35 PM ET

    Jan 6- KaloBios Pharmaceuticals Inc said it would discontinue the development of its drug for lung infections in cystic fibrosis patients after it failed in a mid-stage study, wiping off more than half of its market value. The drug, KB001-A, failed to buy patients more time before taking antibiotics for their worsening respiratory tract symptoms.

  • Jan 5- Cempra Inc moved a step closer to approval for its lead antibiotic, solithromycin, after an oral version of the potential blockbuster met the main goal in a late-stage trial. Shares of Cempra, among a clutch of smaller companies developing treatments to fight super-bugs, rose as much as 18 percent to $27.10 in early trading on Monday. WBB Securities' Steve...

  • Jan 5- Cempra Inc moved a step closer to approval of its lead antibiotic, solithromycin, after an oral version of the potential blockbuster met the main goal in a late-stage trial. Data showed solithromycin actually outperformed moxifloxacin by a slight margin, Cempra said on Sunday. North Carolina- based Cempra is also evaluating an intravenous formulation of...

  • LOS ANGELES, Dec 23- Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly...

  • LOS ANGELES, Dec 23- Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly...

  • UPDATE 1-Pozen says FDA rejects lead drug again Wednesday, 17 Dec 2014 | 8:18 AM ET

    Dec 17- Pozen Inc said two versions of its experimental heart drug were rejected for the second time by the U.S. Food and Drug Administration, which again cited deficiencies in the manufacturing plant of a supplier of an active ingredient. Pozen's shares fell nearly 23 percent to $6.99 in premarket trading on Wednesday. Pozen, which first received the rejection...

  • Dec 12- Cempra Inc has no plans for now to sell itself, its CEO said, brushing off talk that the company is a potential target as big drugmakers set their sights on antibiotic developers. The deal stirred speculation that developers such as Cempra could also be takeover targets. I know a lot of other biotechs are, " Cempra Chief Executive Prabha Fernandes said in an...

  • LONDON, Dec 10- Drugmakers are finally getting more bang for their scientific buck, with the rate of return on pharmaceutical research and development increasing for the first time since 2010.. So far this year the U.S. Food and Drug Administration, which acts as gatekeeper to the world's biggest market, has approved 35 new products, up from 27 in the whole of 2013...